NOVOB80:BKK
Novo
1,31 THB
arrow_upward
+1,55%(+0,020) 1D
13. 10., 2:39:56 GMT+7 · THB
search
Všechny symboly
| Symbol | Cena | Změna | Změna (%) |
|---|
insights_autoGenerování hlavních statistik pro NOVOB80…
Otevřít
1,28 THB
Max.
1,30 THB
Min.
1,27 THB
Trž. kap.
129,60 mld.
Prům. obj.
3,96 mil.
Objem
2,71 mil.
52týd. max.
2,02 THB
52týd. min.
1,12 THB
Akcie v oběhu
3,00 mld.
Počet zaměstnanců
67 tis.
Otevřít
1,28 THB
Max.
1,30 THB
Min.
1,27 THB
Trž. kap.
129,60 mld.
Prům. obj.
3,96 mil.
Objem
2,71 mil.
52týd. max.
2,02 THB
52týd. min.
1,12 THB
Akcie v oběhu
3,00 mld.
Počet zaměstnanců
67 tis.
Zpravodajské články
Z webových zdrojů a od partnerů z oblasti zpravodajství
Zacks Investment Research
·
před 12 hodinami
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
Investing.com India
·
před 13 hodinami
BMO cuts Novo Nordisk stock price target on Ozempic headwinds By Investing.com
Foreign Policy Journal
·
před 13 hodinami
Novo Nordisk (NYSE: NVO) Repurchases Over 23 Million B Shares Under DKK 15 Billion Buyback Programme
Yahoo Finance
·
před 17 hodinami
Novo Nordisk A/S - share repurchase programme
Profil
Novo is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark's domestic economy, and it became the highest valued company in Europe. Wikipedia
Informace o Novo
Generální ředitelMaziar Mike Doustdar
Zaměstnanci66,7 tis.
Založeno1923
ÚstředíBagsværd, Hovedstaden, Dánsko
Odvětví-